| Primary |
| Product Used For Unknown Indication |
29.0% |
| Malignant Melanoma |
12.9% |
| Drug Use For Unknown Indication |
11.2% |
| Prostate Cancer |
7.6% |
| Neutropenia |
5.4% |
| Diffuse Large B-cell Lymphoma |
4.2% |
| Premedication |
3.8% |
| Breast Cancer |
3.6% |
| Crohn's Disease |
3.3% |
| Glioblastoma Multiforme |
2.5% |
| Lymphoma |
2.5% |
| Metastatic Malignant Melanoma |
2.0% |
| Nausea |
1.8% |
| Myelodysplastic Syndrome |
1.7% |
| Non-hodgkin's Lymphoma |
1.7% |
| Lung Neoplasm Malignant |
1.6% |
| Prostate Cancer Metastatic |
1.6% |
| B-cell Lymphoma |
1.2% |
| Colony Stimulating Factor Prophylaxis |
1.2% |
| Pain |
1.2% |
|
| Vomiting |
13.8% |
| Syncope |
11.8% |
| Pyrexia |
9.8% |
| Hypotension |
6.6% |
| Pulmonary Embolism |
6.6% |
| Urticaria |
5.2% |
| White Blood Cell Count Decreased |
4.9% |
| Loss Of Consciousness |
4.6% |
| Weight Decreased |
4.3% |
| Dyspnoea |
3.9% |
| Nausea |
3.6% |
| Death |
3.3% |
| Adverse Event |
3.0% |
| Atrial Fibrillation |
3.0% |
| Chest Pain |
2.6% |
| Pain |
2.6% |
| Presyncope |
2.6% |
| Rash |
2.6% |
| Unevaluable Event |
2.6% |
| White Blood Cell Count Increased |
2.6% |
|
| Secondary |
| Product Used For Unknown Indication |
36.7% |
| Malignant Melanoma |
29.9% |
| Diffuse Large B-cell Lymphoma |
13.8% |
| Bone Marrow Conditioning Regimen |
2.9% |
| Non-hodgkin's Lymphoma |
1.9% |
| Pain |
1.6% |
| Drug Use For Unknown Indication |
1.3% |
| Prostate Cancer |
1.3% |
| Acute Myeloid Leukaemia |
1.0% |
| Alveolar Proteinosis |
1.0% |
| Nausea |
1.0% |
| Neuroblastoma |
1.0% |
| Prostate Cancer Metastatic |
1.0% |
| Lung Neoplasm Malignant |
0.9% |
| Mantle Cell Lymphoma |
0.9% |
| Anxiety |
0.9% |
| Insomnia |
0.8% |
| Blood Pressure Increased |
0.7% |
| Haematopoietic Stem Cell Mobilisation |
0.7% |
| Neutropenia |
0.6% |
|
| Pulmonary Embolism |
14.4% |
| Vomiting |
8.3% |
| Thrombocytopenia |
6.7% |
| Sepsis |
6.1% |
| Septic Shock |
5.6% |
| Urticaria |
5.6% |
| Hypotension |
5.0% |
| Joint Range Of Motion Decreased |
5.0% |
| Hyperhidrosis |
4.4% |
| Neoplasm Malignant |
4.4% |
| Weight Decreased |
4.4% |
| Gastritis |
3.9% |
| Abdominal Pain |
3.3% |
| Dehydration |
3.3% |
| Diarrhoea |
3.3% |
| Nausea |
3.3% |
| Pharyngeal Oedema |
3.3% |
| Pruritus |
3.3% |
| White Blood Cell Count Decreased |
3.3% |
| Hepatitis Alcoholic |
2.8% |
|
| Concomitant |
| Product Used For Unknown Indication |
16.0% |
| Non-small Cell Lung Cancer |
14.1% |
| Prostate Cancer |
12.9% |
| Drug Use For Unknown Indication |
10.9% |
| Inflammatory Bowel Disease |
6.2% |
| Osteoporosis |
4.0% |
| Crohn's Disease |
3.7% |
| Prophylaxis |
3.7% |
| Premedication |
3.1% |
| Acute Myeloid Leukaemia |
2.8% |
| Bone Marrow Conditioning Regimen |
2.8% |
| Multiple Myeloma |
2.8% |
| Nausea |
2.6% |
| Vitiligo |
2.6% |
| Metastases To Bone |
2.3% |
| Neutropenia |
2.3% |
| Acute Lymphocytic Leukaemia |
1.9% |
| Pain |
1.9% |
| Hypercalcaemia Of Malignancy |
1.7% |
| Hypercholesterolaemia |
1.7% |
|
| Weight Decreased |
15.7% |
| Weight Increased |
8.7% |
| Device Related Infection |
7.0% |
| Wound |
7.0% |
| Myelodysplastic Syndrome |
6.1% |
| Pyrexia |
6.1% |
| Vomiting |
6.1% |
| Pneumonia |
4.3% |
| Death |
3.5% |
| Iron Deficiency Anaemia |
3.5% |
| Mucosal Inflammation |
3.5% |
| Syncope |
3.5% |
| Urinary Tract Infection |
3.5% |
| Venous Thrombosis |
3.5% |
| Visual Disturbance |
3.5% |
| White Blood Cell Count Decreased |
3.5% |
| White Blood Cell Count Increased |
3.5% |
| Diverticulum |
2.6% |
| Joint Swelling |
2.6% |
| Loss Of Consciousness |
2.6% |
|
